Abstract
The Omnifit-HA femoral component has shown excellent results in early and mid-term industry sponsored multi-center clinical trials. To validate these results, an independent cohort of patients was followed prospectively for an average of ten years.
The senior author performed 103 consecutiveuncemented primary total hip arthroplasties in 89 patients from July 1991 to December 1996. The components implanted were the Omnifit-HA femoral stem and the Omnifit PSL porous coated acetabular shell. The cohort, with a mean ageat the time of the index procedure of 52 ± 9 years, was comprised of 45females and 58 males. The mean follow up was 10.3 years (range 7.3 – 12.7years). Two independent observers who were not part of the surgical team performed clinical and radiographic evaluations.
The senior author performed 103 consecutiveuncemented primary total hip arthroplasties in 89 patients from July 1991 to December 1996. The components implanted were the Omnifit-HA femoral stem and the Omnifit PSL porous coated acetabular shell. The cohort, with a mean ageat the time of the index procedure of 52 ± 9 years, was comprised of 45females and 58 males. The mean follow up was 10.3 years (range 7.3 – 12.7years). Two independent observers who were not part of the surgical team performed clinical and radiographic evaluations.
The Omnifit-HA femoral component continues to show excellent clinical results as indicated by the multi-center trials. This is the first study to report 10-year follow up by an independent surgeon. Despite the younger mean age, relatively high polyethylene wear, and 10% rate of lysis in the acetabulum, the femoral stem had a 100%survivorship. This supports the theory that proximal circumferential bone in growth affords protection against the migration of wear debris along the femoral stem.
Correspondence should be addressed to Richard Komistek, PhD, International Society for Technology in Arthroplasty, PO Box 6564, Auburn, CA 95604, USA. E-mail: ista@pacbell.net
